Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Brooke MacUch

Nurse Practitioner Wilkes Barre, PA Nurse Practitioner

NPI 1326709569 CMS profile 11361664

1000 E Mountain Dr, Wilkes Barre, PA 18711

Open in the dashboard

General payments

$2,978

87 records reported · program years 2022–2025

Research payments

$1,000

Paid to them · 3 records reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brooke MacUch of Wilkes Barre, PA is reported in the CMS Open Payments database as having received $2,978 across 87 general payments and $1,000 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,074 33
2024 General $1,179 34
2023 General $636 15
2023 Research $1,000 3
2022 General $87 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brooke MacUch
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Brooke MacUch were reported at $1,074. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Brooke MacUch Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $87 $152 $48–$470 $149
2023 $636 $166 $54–$529 $160
2024 $1,179 $173 $55–$556 $164
2025 $1,074 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Medtronic, Inc. $1,623 61 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $932 21 payments
  3. Janssen Pharmaceuticals, Inc $135 1 payment
  4. AstraZeneca Pharmaceuticals LP $122 1 payment
  5. Novo Nordisk Inc $122 1 payment
  6. Boston Scientific Corporation $44 2 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,978 87 payments
Products named General payments · program years 2022–2025
  1. LifeVest $932 21 payments
  2. SelectSecure $772 39 payments
  3. COBALT DR MRI SURESCAN $253 3 payments
  4. Micra $149 6 payments
  5. XARELTO $135 1 payment
  6. WAINUA $122 1 payment
  7. LINQ II $58 3 payments
  8. AZURE XT DR MRI SURESCAN $26 1 payment
  9. ACCOLADE SR $22 1 payment
  10. INGEVITY+ $22 1 payment
  11. Other $13 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2022–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,000 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

763

Median for Nurse Practitioner: 389

Drug cost

$180,692

Median for Nurse Practitioner: $21,885

Branded share of claims

28%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 155 $153,757
Xarelto Rivaroxaban Brand 16 $15,259
Metoprolol Succinate Generic 254 $4,802
Sucralfate Generic 26 $2,151
Amiodarone Hcl Generic 92 $1,283
Flecainide Acetate Generic 40 $1,186
Sotalol Sotalol Hcl Brand 43 $944
Carvedilol Generic 24 $336
Torsemide Generic 11 $236
Metoprolol Tartrate Generic 32 $199

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$21,641

Medicare's payments for the services billed

Medicare patients

289

Average age 76

Services billed

516

111 women, 178 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Heart failure 49%
Arthritis 49%
Ischemic heart disease 48%
Chronic kidney disease 39%
Diabetes 34%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

90 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record